AL002 is a monoclonal antibody intended to enhance the activity of
AL002 is being developed by Alector for the treatment of Alzheimer’s disease and Alector is responsible for the execution of Phase 1 and Phase 2 studies. Following its exercise of an option for a program, AbbVie will be responsible for certain development activities and global commercialization.
Type of MoleculeBiologic
Product TypeNew Indication
|Potential Indication||Region||Phase (1, 2, 3, Submitted, Approved)|
|Alzheimer's Disease (AD)||n/a||